GRAIL, Inc.GRALEarnings & Financial Report
Nasdaq · Health Care · Services-Medical Laboratories
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
Revenue
$26.7M
Gross Profit
N/A
Operating Profit
$-227.4M
Net Profit
$-218.9M
Gross Margin
N/A
Operating Margin
-851.1%
Net Margin
-819.3%
YoY Growth
N/A
EPS
$-7.05
GRAIL, Inc. Q1 FY2024 Financial Summary
GRAIL, Inc. reported revenue of $26.7M for Q1 FY2024, with a net profit of $-218.9M (down 13.0% YoY) (-819.3% margin).
Key Financial Metrics
| Total Revenue | $26.7M |
|---|---|
| Net Profit | $-218.9M |
| Gross Margin | N/A |
| Operating Margin | -851.1% |
| Report Period | Q1 FY2024 |
GRAIL, Inc. Annual Revenue by Year
GRAIL, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $147.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $147.2M |
| 2024 | $125.6M |
GRAIL, Inc. Quarterly Revenue & Net Profit History
GRAIL, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $43.6M | +14.0% | $-99.2M | -227.5% |
| Q3 FY2025 | $36.2M | +26.3% | $-89.0M | -245.8% |
| Q2 FY2025 | $35.5M | +11.2% | $-114.0M | -320.7% |
| Q1 FY2025 | $31.8M | +19.1% | $-106.2M | -333.6% |
| Q4 FY2024 | $38.3M | +84.6% | $-97.1M | -253.8% |
| Q3 FY2024 | $28.7M | — | $-125.7M | -438.7% |
| Q2 FY2024 | $32.0M | +42.6% | $-1.6B | -4958.8% |
| Q1 FY2024 | $26.7M | — | $-218.9M | -819.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.7M | $32.0M | $28.7M | $38.3M | $31.8M | $35.5M | $36.2M | $43.6M |
| YoY Growth | N/A | 42.6% | N/A | 84.6% | 19.1% | 11.2% | 26.3% | 14.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | N/A | $3.27B | $3.12B | $2.98B | $2.85B | $2.70B | $2.60B | $2.92B |
| Liabilities | N/A | $574.5M | $530.3M | $479.9M | $433.9M | $387.9M | $361.1M | $344.2M |
| Equity | N/A | $2.70B | $2.59B | $2.50B | $2.41B | $2.31B | $2.24B | $2.58B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-207.3M | $-171.8M | $-104.6M | $-95.0M | $-77.0M | $-63.2M | $-63.8M |